Rise in prevalence of rabies in developing countries, increase in number of dog bites and rising number of stray dogs and presence of large market players who manufactures rabies vaccine is anticipated to boost the growth of rabies vaccine market. Moreover, rise in awareness among the population regarding importance of vaccination and increase in number of post-exposure prophylaxis is anticipated to drive the growth of the global rabies vaccine market..

预计发展中国家狂犬病流行率上升，狗咬伤数量增加，流浪狗数量增加，制造狂犬病疫苗的大型市场参与者的出现将推动狂犬病疫苗市场的增长。此外，预计人口对疫苗接种重要性的认识提高以及暴露后预防数量的增加将推动全球狂犬病疫苗市场的增长。。

PORTLAND, Ore., Nov. 25, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, 'Rabies vaccine Market by Type (Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Others), Prophylaxis Type (Pre-Exposure Prophylaxis and Post Exposure Prophylaxis), Application (Human and Animal) and End User (Hospitals, Veterinary Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032'. According to the report, the global rabies vaccine market was valued for $1,207.03 million in 2022, and is projected to reach $1,903.17 million by 2032, registering a CAGR of 4.7% from 2023 to 2032..

俄勒冈州波特兰市，2023年11月25日/PRNewswire/-联合市场研究发表了一份报告，标题为“狂犬病疫苗市场类型”（鸡胚细胞狂犬病疫苗，韦罗细胞狂犬病疫苗，人类二倍体细胞疫苗等）），预防类型（暴露前预防和暴露后预防），应用（人类和动物）和最终用户（医院，兽医诊所等）：全球机会分析和行业预测，2023-2032'。据报道，到2022年，全球狂犬病疫苗市场价值为1.207亿美元，预计到2032年将达到1.903.17亿美元，从2023年到2032年的CAGR为4.7%。。

Request Sample of the Report on Rabies Vaccine Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/3264

要求狂犬病疫苗市场报告样本2032-https://www.alliedmarketresearch.com/request-sample/3264

Prime determinants of growth

增长的主要决定因素

Rise in prevalence of rabies, increase in post exposure prophylaxis for rabies and increase in number of initiatives by government for eradication rabies is anticipated to boost the growth of market. However, high cost of rabies vaccine is anticipated to hinder the growth of market. On the contrary, high presence of rabies vaccine providers, rise in number of adoptions of key strategies by manufacturers of rabies vaccine is to witness growth during the forecast period..

狂犬病流行率上升，狂犬病暴露后预防措施增加，政府根除狂犬病的举措数量增加，预计将推动市场增长。然而，狂犬病疫苗的高成本预计会阻碍市场的增长。相反，狂犬病疫苗供应商的大量存在，狂犬病疫苗制造商采用关键策略的数量增加，将在预测期间见证增长。。

Report coverage & details:

报告覆盖范围和详细信息：

Report Coverage

报告报道

Details

细节

Forecast Period

预测期

2023–2032

2023–2032

Base Year

基准年

2022

2022

Market Size in 2022

2022年的市场规模

$1,207.03 million

1.20703亿美元

Market Size in 2032

2032年的市场规模

$1,903.17 million

$190317万

CAGR

CAGR

4.7 %

4.7 %

No. of Pages in Report

报告中的页数

451

451

Segments covered

涵盖的细分

Type, Prophylaxis Type Application, End User and Region.

类型，预防类型应用，最终用户和地区。

Drivers

驱动程序

Rise in prevalence of rabies in developing countries High presence of rabies vaccine manufacturers

发展中国家狂犬病流行率上升狂犬病疫苗制造商人数众多

Opportunities

机会

Rise in adoption of number of strategies by market players of rabies vaccine

狂犬病疫苗市场参与者采用战略数量的上升

Restraints

约束

High cost of rabies vaccine

狂犬病疫苗成本高

Want to Explore More, Connect to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/3264

想要探索更多，请连接我们的分析师-https://www.alliedmarketresearch.com/connect-to-analyst/3264

The chick embryo cells rabies vaccine segment to maintain its leadership status throughout the forecast period

鸡胚细胞狂犬病疫苗部门在整个预测期间保持其领导地位

By product type, the chick embryo cells rabies vaccine segment held the highest market share in 2022, accounting for nearly two-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to the high presence of market players who manufactures chick embryo cells rabies vaccine.

副产品类型，鸡胚细胞狂犬病疫苗细分在2022年占有最高的市场份额，占全球狂犬病疫苗市场收入的近五分之二，估计在整个预测期间保持其领导地位，因为高制造鸡胚细胞狂犬病疫苗的市场参与者。

However, the human diploid cell vaccine segment is projected to manifest significant growth with a CAGR of 5.3% from 2023 to 2032, owing to the effectiveness and safety associated to human diploid cell vaccine..

然而，由于与人二倍体细胞疫苗相关的有效性和安全性，预计人二倍体细胞疫苗区段在2023年至2032年期间表现出显着生长，CAGR为5.3%。。

The post exposure prophylaxis segment to maintain its leadership status throughout the forecast period

暴露后预防部门在整个预测期间保持领导地位

By prophylaxis type, the post exposure prophylaxis segment held the highest market share in 2022, accounting for more than three-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in awareness among population regarding post-exposure prophylaxis.

通过预防类型，暴露后预防部分在2022年占有最高的市场份额，占全球狂犬病疫苗市场收入的五分之三以上，预计在整个预测期间将保持其领导地位，因为人们对暴露后预防的认识。

However, the pre-exposure prophylaxis segment is projected to manifest a significant CAGR of 5.1% from 2023 to 2032, owing to rise in number of pre exposure prophylaxis by tourist, healthcare activist, environmentalist and population who are having pets..

然而，由于游客，医疗保健活动家，环保主义者和养宠物的人群暴露前预防的数量增加，预计暴露前预防部分从2023年到2032年将显示5.1%的显着CAGR。。

The human segment to maintain its leadership status throughout the forecast period

在整个预测期间保持领导地位

By application, the human segment held the highest market share in 2022, accounting for more than three-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in awareness among the population regarding importance of vaccination.

通过应用，人类细分市场在2022年占有最高的市场份额，占全球狂犬病疫苗市场收入的五分之三以上，并且由于人口对重要性的认识提高，估计在整个预测期间将保持其领导地位。接种疫苗。

However, the animal segment is projected to manifest a significant CAGR of 5.0% from 2023 to 2032..

然而，预计从2023年到2032年，动物部分的CAGR显着为5.0%。。

The hospitals segment to maintain its leadership status throughout the forecast period

医院部门在整个预测期间保持领导地位

By end user, the hospitals segment held the highest market share in 2022, accounting for more than two-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in number of vaccinations in hospitals. However, the veterinary clinics segment is projected to manifest a significant CAGR of 5.2% from 2023 to 2032..

就最终用户而言，医院部门在2022年占有最高的市场份额，占全球狂犬病疫苗市场收入的五分之二以上，预计在整个预测期间将保持其领导地位，因为疫苗接种数量有所增加医院。然而，从2023年到2032年，兽医诊所部分预计将显示5.2%的显着CAGR。。

For Procurement Information- https://www.alliedmarketresearch.com/purchase-enquiry/3264

采购信息-https://www.alliedmarketresearch.com/purchase-enquiry/3264

North America to maintain its dominance by 2032

到2032年北美将保持主导地位

By region, North America held the highest market share in terms of revenue in 2022, accounting for more than one-third of the global rabies vaccine market revenue. This is attributed to high presence of rabies vaccine manufacturers in North America and rising number of initiatives taken by government for animal vaccination.

按地区划分，北美在2022年的收入方面占有最高的市场份额，占全球狂犬病疫苗市场收入的三分之一以上。这归因于北美狂犬病疫苗制造商的大量存在以及政府为动物疫苗接种采取的举措数量不断增加。

However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.2% from 2023 to 2032 and is likely to dominate the market during the forecast period, owing to increase in awareness among the population regarding importance of rabies vaccination, rise in number of dog bites and increase in number of stray dogs in developing countries like India.

然而，由于人口对狂犬病疫苗接种重要性的认识提高，亚太地区预计将在2023年至2032年期间见证最快的5.2%的CAGR，并可能在预测期间占据市场主导地位。印度等发展中国家的狗咬伤和流浪狗数量增加。

.

.

Leading Market Players:

领先的市场参与者：

Bharat Biotech International Limited

巴拉特生物技术国际有限公司

Sanofi

赛诺菲

Boehringer Ingelheim International Gmbh

勃林格殷格翰国际有限公司

Novartis Ag

诺华公司

Cadila Pharmaceuticals Ltd

卡迪拉制药有限公司

Merck And Co., Inc.

默克公司股份有限公司。

Serum Institute of India Pvt. Ltd.

印度血清研究所Pvt。Ltd。

Zoetis Inc.

Zoetis股份有限公司。

Elanco Animal Health Incorporated.

Elanco Animal Health Incorporated。

Virbac Sa

Virbac Sa

The report provides a detailed analysis of these key players of the global rabies vaccine market. These players have adopted different strategies such as agreement, partnership, acquisition, and business expansion to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. .

该报告详细分析了全球狂犬病疫苗市场的这些主要参与者。这些参与者采取了协议，合作关系，收购和业务扩张等不同策略，以增加其市场份额并维持不同地区的主导份额。该报告对于突出业务绩效，运营细分市场，产品组合以及市场参与者展示竞争情景的战略举措非常有价值。 .

Comprehensive Healthcare Industry Research Studies:

综合医疗行业研究：

mHealth Market - Global Opportunity Analysis and Industry Forecast, 2022–2032

移动医疗市场-全球机会分析和行业预测，2022-2032

Biomaterials Market - Global Opportunity Analysis and Industry Forecast, 2022–2032

生物材料市场-全球机会分析和行业预测，2022-2032

Flow Cytometry Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

流式细胞术市场-全球机会分析和行业预测，2022-2032

Healthcare IT Market - Global Opportunity Analysis and Industry Forecast, 2022–2032

医疗保健IT市场-全球机会分析和行业预测，2022-2032

MRI System Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

MRI系统市场-全球机会分析和行业预测，2022-2032

About Allied Market Research:

关于联合市场研究：

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of 'Market Research Reports' and 'Business Intelligence Solutions.' AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

Allied Market Research（AMR）是位于特拉华州威尔明顿的Allied Analytics LLP的全方位市场研究和商业咨询部门。联合市场研究为全球企业以及中小企业提供无与伦比的“市场研究报告”和“商业智能解决方案”质量AMR的目标是提供业务见解和咨询，以帮助其客户做出战略业务决策并在各自的市场领域实现可持续增长。

AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI..

AMR为11个行业提供服务，包括生命科学，消费品，材料和化学品，建筑和制造，食品和饮料，能源和电力，半导体和电子，汽车和运输，ICT和媒体，航空航天和国防以及BFSI。。

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success.

我们与各公司建立专业的公司关系，这有助于我们挖掘市场数据，帮助我们生成准确的研究数据表，并确认我们市场预测的最高准确性。联合市场研究首席执行官Pawan Kumar致力于激励和鼓励与该公司相关的每个人保持高质量的数据并以各种可能的方式帮助客户取得成功。

Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry..

我们发布的报告中提供的每个数据都是通过与相关领域领先公司的高级官员的初步访谈提取的。我们的二级数据采购方法包括深入的在线和离线研究以及与行业知识渊博的专业人士和分析师的讨论。。

ContactDavid Correa1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.Toll Free: +1-800-792-5285Int'l: +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1-855-550-5975[email protected] Web: https://www.alliedmarketresearch.com  Follow Us on: LinkedIn.

联系方式：David Correa1209 Orange Street，Corporation Trust Center，Wilmington，New Castle，Delaware 19801 USA.免费电话：+1-800-792-5285Int'l:+1-503-894-6022UK:+44-845-528-1300Hong Kong:+852-301-84916India（Pune）：+91-20-66346060传真：+1-855-550-5975[电子邮件保护]网络：https://www.alliedmarketresearch.com跟随我们：LinkedIn。

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

标志：https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

SOURCE Allied Market Research

来源联合市场研究